ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31)
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) of $1.50 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-26.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2013-04-26
- ELI LILLY AND COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $1.50M.
- ELI LILLY AND COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2012 was $5.90M.
- ELI LILLY AND COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2011 was -$5.80M.
- ELI LILLY AND COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2010 was -$5.80M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2013-03-31 | $1.50M 10-Q · filed 2013-04-26 | |
| 2012-12-31 | $5.90M 10-K · filed 2013-02-21 | |
| 2011-12-31 | -$5.80M 10-K · filed 2013-02-21 | |
| 2010-12-31 | -$5.80M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |